• About Nektar
  • Our Leadership
  • Corporate Giving
  • Locations
  • Contacts
• Pipeline
  • Pipeline Overview
  • Nektar Proprietary Products
  • Nektar Partnered Products
  • Drug Development Platforms
• Partners
  • Nektar Partners
• Investor Relations
  • Press Releases
  • Stock Information
  • Financial Events Calendar
  • Analyst Coverage
  • Annual and Financial Reports
  • Corporate Governance
  • Investor Contacts
  • FAQ
  • Investor Advisory
• Media Room
  • Lead Product Backgrounder
  • Press Releases
  • Press Kit
  • Media Contacts
• Information Center
  • Scientific & Partnering Events
  • Multimedia
  • Email Alerts
• Careers
  • Life at Nektar
  • Career Opportunities
  • Recruitment Calendar
  • Summer Internships
  • Benefits
  • Recruiting Information
  • Nektar Employee Foundation

• Lead Product Backgrounder
  • Product Info: NKTR-061
  • Product Info: NKTR-102
  • Product Info: NKTR-118
• Press Releases
• Press Kit
• Media Contacts

Data Presentations from AACR 2008 — April 14, 2008

• Press Release: Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting — April 14, 2008
• Poster #766: Enhanced anti-tumor activity of NKTR-102, a novel PEGylated-irinotecan, when administered in combination with bevacizumab in a mouse model of human colorectal tumors — April 14, 2008
• Poster #5741: NKTR-102, a novel PEGylated-irinotecan, has an enhanced pharmacokinetic profile with reduced gastrointestinal and hematopoietic toxicity compared to irinotecan with repeat dosing in dogs — April 14, 2008
• Poster #5742: NKTR-102, a novel PEGylated-irinotecan, has a superior acute safety, tolerability, and pharmacokinetic profile compared to irinotecan in rats and dogs — April 14, 2008

Data Presentations from 2007 AACR-NCI-EORTC International Conference — October 25, 2007

• Press Release: NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition in Multiple Preclinical Tumor Models — October 25, 2007
• Poster #C10: NKTR-102, a novel polyethylene glycol conjugate of irinotecan, has improved anti-tumor activity in three mouse xenograft models — October 25, 2007
• Poster #C157: NKTR-102, a novel PEGylated-irinotecan conjugate, results in sustained tumor growth inhibition in mouse models of human colorectal and lung tumors that is associated with increased and sustained tumor SN38 exposure — October 25, 2007

Data Presentations from ECCO 14 Conference — September 27, 2007

• Press Release: NKTR-102 (PEG-Irinotecan) Demonstrates Significant Anti-Tumor Activity and Improved Time-Concentration Profile in Preclinical Studies Presented at ECCO 14 — September 27, 2007
• Poster #722: Anti-tumor activity and pharmacokinetics of NKTR-102, a novel PEGylated-irinotecan conjugate, in irinotecan-resistant colorectal tumors implanted in mice — Presented at ECCO 14 (14th Annual European Cancer Conference) — September 27, 2007
• Poster #727: NKTR-102, a novel PEGylated-irinotecan conjugate, demonstrates improved pharmacokinetics with sustained exposure of irinotecan and its active metabolite-Presented at ECCO 14 (14th Annual European Cancer Conference) — September 27, 2007